Prasugrel or Ticagrelor for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Does it Matter?

JACC Cardiovasc Interv. 2018 Aug 27;11(16):1587-1589. doi: 10.1016/j.jcin.2018.04.047. Epub 2018 May 24.

Authors

Jay Giri¹, Ashwin Nathan²

Affiliations

¹ Cardiovascular Outcomes, Quality, & Evaluative Research Center, Leonard Davis Institute of Health Economics, Cardiovascular Medicine Division, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: [email protected].
² Cardiovascular Outcomes, Quality, & Evaluative Research Center, Leonard Davis Institute of Health Economics, Cardiovascular Medicine Division, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 29805110
DOI: 10.1016/j.jcin.2018.04.047

No abstract available

Keywords: ACS; PCI; antiplatelet therapy.

Publication types

Editorial
Comment

MeSH terms

Acute Coronary Syndrome*
Biomarkers
Clopidogrel
Cross-Over Studies
Humans
Percutaneous Coronary Intervention*
Prasugrel Hydrochloride
Ticagrelor
Treatment Outcome

Substances

Biomarkers
Clopidogrel
Prasugrel Hydrochloride
Ticagrelor